中文名 | 雷莫拉宁 |
英文名 | Ramoplanin |
别名 | 雷莫拉宁 雷莫拉宁复合物 |
英文别名 | A 16686 A 16686A Ramoplanin MDL 62,198 Ramoplaninr Ray mora ning RaMoplanin coMplex Antibiotic A 16686 RaMoplanin(A 16686,A 16686A) Glycolipodepsi peptide antibiotic produced by actinoplanes species ATCC33076 Antibiotic A 16686, 2-(((3alpha,5beta)-3-hydroxy-7,24-dioxocholan-24-yl)amino)-, (SP-4-2)- Glycolipodepsi peptide antibiotic produced by actinoplanes species ATCC33076. Ramoplanin is a complex antibiotic consisting of a main component designated as ramoplanin A2 and a small amount of related substances, ramoplanin A1, A'1, A'2, A3, and A'3 |
CAS | 76168-82-6 |
化学式 | C106H170ClN21O30 |
分子量 | 2254.0597 |
InChI | InChI=1/C106H170ClN21O30/c1-8-9-10-11-15-22-80(140)114-75(50-78(110)138)96(147)118-76(51-79(111)139)97(148)124-86(60-25-36-66(133)37-26-60)102(153)117-72(21-17-46-109)92(143)120-83(56(6)130)100(151)126-89(63-31-42-69(136)43-32-63)105(156)127-88(62-29-40-68(135)41-30-62)104(155)121-82(55(5)129)99(150)119-74(48-58-18-13-12-14-19-58)95(146)116-71(20-16-45-108)93(144)123-87(61-27-38-67(134)39-28-61)103(154)122-84(57(7)131)101(152)125-85(59-23-34-65(132)35-24-59)98(149)112-52-81(141)115-73(47-53(2)3)94(145)113-54(4)91(142)128-90(106(157)158)64-33-44-77(137)70(107)49-64/h10-15,18-19,22,53-57,59-77,82-90,129-137H,8-9,16-17,20-21,23-52,108-109H2,1-7H3,(H2,110,138)(H2,111,139)(H,112,149)(H,113,145)(H,114,140)(H,115,141)(H,116,146)(H,117,153)(H,118,147)(H,119,150)(H,120,143)(H,121,155)(H,122,154)(H,123,144)(H,124,148)(H,125,152)(H,126,151)(H,127,156)(H,128,142)(H,157,158)/b11-10-,22-15-/t54-,55+,56+,57+,59?,60?,61?,62?,63?,64?,65?,66?,67?,68?,69?,70?,71-,72-,73+,74+,75+,76?,77?,82+,83-,84+,85?,86-,87?,88-,89-,90?/m1/s1 |
InChIKey | FSBZBQUUCNYWOK-KFTDLNJOSA-N |
熔点 | 210-230° |
比旋光度 | D20 +78.3° (c = 1.04 in H2O) |
溶解度 | H2O: 可溶物10mg/mL |
存储条件 | -20°C |
外观 | 粉末 |
颜色 | White to Off-White |
体外研究 | Ramoplanin exerts its bactericidal activity against gram-positive aerobic and anaerobic bacteria by blocking peptidoglycan synthesis via lipid II. |
体内研究 | Ramoplanin (100, 500 μg/ml; p.o.; for 8 days) suppresses vancomycin-resistant Enterococcus (VRE) to undetectable level during treatment. Animal Model: Female CF1 mice (25-30 g) Dosage: 100 μg/ml, 500 μg/ml Administration: Oral administration; for 8 days Result: Developed undetectable levels of VRE in stool during treatment. |
危险品标志 | Xi - 刺激性物品 |
风险术语 | 41 - 对眼睛有严重伤害。 |
安全术语 | S26 - 不慎与眼睛接触后,请立即用大量清水冲洗并征求医生意见。 S39 - 戴护目镜或面具。 |
WGK Germany | nwg |
RTECS | VE5050000 |